Next Article in Journal
Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich’s Ataxia: A New Synthetic Route
Previous Article in Journal
Essential Oils from Different Plant Parts of Eucalyptus cinerea F. Muell. ex Benth. (Myrtaceae) as a Source of 1,8-Cineole and Their Bioactivities
Previous Article in Special Issue
Vasoinhibins Prevent Bradykinin-Stimulated Endothelial Cell Proliferation by Inactivating eNOS via Reduction of both Intracellular Ca2+ Levels and eNOS Phosphorylation at Ser1179
Pharmaceuticals 2011, 4(12), 1551-1577; doi:10.3390/ph4121551
Review

Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix

1
 and 1,2,*
Received: 14 October 2011; in revised form: 24 November 2011 / Accepted: 25 November 2011 / Published: 2 December 2011
(This article belongs to the Special Issue Angiogenesis Inhibitors)
View Full-Text   |   Download PDF [789 KB, uploaded 2 December 2011]   |   Browse Figures
Abstract: Angiogenesis, a neovascularization process induced from the existing parent blood vessels, is a prerequisite for many physiological and pathological conditions. Under physiological conditions it is regulated by a balance between endogenous angioinhibitors and angioactivators, and an imbalance between them would lead to pathological conditions such as cancer, age-related macular degeneration (AMD), diabetic retinopathy, cardiovascular diseases, etc. Several proteolytically generated endogenous molecules have been identified which exhibit angioinhibition and/or antitumor activities. These angioinhibitors interact with endothelial and tumor cells by binding to distinct integrins and initiate many of their intracellular signaling mechanisms regulating the cell survival and or apoptotic pathways. The present review will focus on the extracellular matrix derived angioinhibitors, and their mechanisms of actions that point to the clinical significance and therapeutic implications.
Keywords: extracelluar matrix; endogenous angioinhibitors; tumor angiogenesis; arresten; canstatin; tumstatin; endostatin; endorepellin; angiostatin; prothrombin kringle domain 2; thrombospondin; vasohibin; PEX domain; integrin signaling extracelluar matrix; endogenous angioinhibitors; tumor angiogenesis; arresten; canstatin; tumstatin; endostatin; endorepellin; angiostatin; prothrombin kringle domain 2; thrombospondin; vasohibin; PEX domain; integrin signaling
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Boosani, C.S.; Sudhakar, Y.A. Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix. Pharmaceuticals 2011, 4, 1551-1577.

AMA Style

Boosani CS, Sudhakar YA. Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix. Pharmaceuticals. 2011; 4(12):1551-1577.

Chicago/Turabian Style

Boosani, Chandra Shekhar; Sudhakar, Yakkanti A. 2011. "Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix." Pharmaceuticals 4, no. 12: 1551-1577.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert